Cellular signaling networks are orchestrated by complex interactions between gene expression and ion flux, yet tools for simultaneously visualizing these events in living cells remain limited. Herein, we report two orthogonal gold-nanoparticle-based DNA nanosensors that enable simultaneous imaging of sodium/hydrogen exchanger 1 (NHE1) mRNA and Na+ dynamics in hepatocellular carcinoma cells. The sensing mechanism relies on proximity-dependent fluorescence quenching. For mRNA detection, Cy3-labeled reporter strands hybridize to DNA-functionalized gold nanoparticles (AuNPs), holding the fluorophore close to the quenching surface. Target binding triggers strand displacement, releasing Cy3, and restoring emission. For Na+ detection, a Cy5-labeled substrate strand hybridizes with a Na+-specific DNAzyme anchored on AuNPs. Na+ activates the DNAzyme, cleaving the substrate at a defined site and liberating the Cy5 fluorophore. This dual-sensor system enables the quantitative monitoring of both analytes in living cells. Using this platform, we directly visualize that NHE1 mRNA downregulation suppresses intracellular Na+ accumulation, establishing a regulatory link between gene expression and ion homeostasis. Notably, mRNA-targeted hybridization inhibits cancer-cell migration in a dose-dependent manner, revealing a potential therapeutic mechanism. This approach provides a molecular tool for decoding ion-based signaling networks in cancer biology.
Tau is an intrinsically disordered protein critical to the nervous system, and its aberrant aggregation is a key pathogenic factor in multiple diseases. However, the underlying triggers remain elusive. Here, using in vitro reconstitution and high-resolution imaging, we identify tRNA as a major inducer of tau aberrant aggregation. Mechanistically, tRNA drives the formation of fibrillar aggregates from tau liquid–liquid phase separation (LLPS) condensates via electrostatic interactions, which over time can evolve into pathological aggregates. Moreover, captopril (CAP) effectively inhibits both general and tRNA-induced tau aggregation, positioning CAP as a potential therapeutic candidate. This work offers an avenue for treating aberrant phase separation-induced tau aggregation using small-molecule compounds.
Boru Peng, Quan Deng, Xiaohua Zhu et al.· Langmuir· 0 citations